ARCT
Price
$13.79
Change
+$0.43 (+3.22%)
Updated
Jul 8, 04:59 PM (EDT)
Capitalization
374.26M
33 days until earnings call
CRSP
Price
$54.81
Change
+$3.62 (+7.07%)
Updated
Jul 8, 04:59 PM (EDT)
Capitalization
4.73B
33 days until earnings call
Interact to see
Advertisement

ARCT vs CRSP

Header iconARCT vs CRSP Comparison
Open Charts ARCT vs CRSPBanner chart's image
Arcturus Therapeutics Holdings
Price$13.79
Change+$0.43 (+3.22%)
Volume$16.51K
Capitalization374.26M
CRISPR Therapeutics AG
Price$54.81
Change+$3.62 (+7.07%)
Volume$46.38K
Capitalization4.73B
ARCT vs CRSP Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. CRSP commentary
Jul 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Buy and CRSP is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 09, 2025
Stock price -- (ARCT: $13.80 vs. CRSP: $54.82)
Brand notoriety: ARCT and CRSP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 97% vs. CRSP: 139%
Market capitalization -- ARCT: $374.26M vs. CRSP: $4.73B
ARCT [@Biotechnology] is valued at $374.26M. CRSP’s [@Biotechnology] market capitalization is $4.73B. The market cap for tickers in the [@Biotechnology] industry ranges from $309.49B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileCRSP’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • CRSP’s FA Score: 0 green, 5 red.
According to our system of comparison, both ARCT and CRSP are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 4 TA indicator(s) are bullish while CRSP’s TA Score has 5 bullish TA indicator(s).

  • ARCT’s TA Score: 4 bullish, 4 bearish.
  • CRSP’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than ARCT.

Price Growth

ARCT (@Biotechnology) experienced а +6.24% price change this week, while CRSP (@Biotechnology) price change was +13.01% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.39%. For the same industry, the average monthly price growth was +14.41%, and the average quarterly price growth was +12.94%.

Reported Earning Dates

ARCT is expected to report earnings on Aug 11, 2025.

CRSP is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+9.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.73B) has a higher market cap than ARCT($374M). CRSP YTD gains are higher at: 39.278 vs. ARCT (-18.680). ARCT has higher annual earnings (EBITDA): -63.92M vs. CRSP (-455.24M). CRSP has more cash in the bank: 1.86B vs. ARCT (217M). ARCT has less debt than CRSP: ARCT (42.7M) vs CRSP (219M). ARCT has higher revenues than CRSP: ARCT (131M) vs CRSP (35M).
ARCTCRSPARCT / CRSP
Capitalization374M4.73B8%
EBITDA-63.92M-455.24M14%
Gain YTD-18.68039.278-48%
P/E RatioN/AN/A-
Revenue131M35M374%
Total Cash217M1.86B12%
Total Debt42.7M219M19%
FUNDAMENTALS RATINGS
ARCT vs CRSP: Fundamental Ratings
ARCT
CRSP
OUTLOOK RATING
1..100
6431
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
67
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9594
PRICE GROWTH RATING
1..100
5139
P/E GROWTH RATING
1..100
10081
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (47) in the Pharmaceuticals Major industry is in the same range as CRSP (67) in the Biotechnology industry. This means that ARCT’s stock grew similarly to CRSP’s over the last 12 months.

ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CRSP (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as ARCT (95) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to ARCT’s over the last 12 months.

CRSP's Price Growth Rating (39) in the Biotechnology industry is in the same range as ARCT (51) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to ARCT’s over the last 12 months.

CRSP's P/E Growth Rating (81) in the Biotechnology industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTCRSP
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 27 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JVSCX14.540.13
+0.90%
Janus Henderson Small-Mid Cap Value C
TCIEX26.23N/A
N/A
Nuveen International Eq Idx R6
ALVRX10.65N/A
N/A
American Century Focused Lg Cap Val R
MDDLX10.36N/A
N/A
MassMutual Diversified Value Adm
SMDRX19.33N/A
N/A
Hartford Schroders US MidCap Opps SDR

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with TRDA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+3.29%
TRDA - ARCT
52%
Loosely correlated
+2.73%
RXRX - ARCT
52%
Loosely correlated
+8.72%
ABCL - ARCT
51%
Loosely correlated
-3.47%
RGNX - ARCT
51%
Loosely correlated
+3.68%
MRNA - ARCT
50%
Loosely correlated
+8.83%
More

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with RXRX. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+7.09%
RXRX - CRSP
72%
Closely correlated
+8.72%
BEAM - CRSP
72%
Closely correlated
+5.84%
NTLA - CRSP
66%
Loosely correlated
+8.49%
ALLO - CRSP
63%
Loosely correlated
+3.45%
CRBU - CRSP
62%
Loosely correlated
+15.11%
More